ERAS
HOLD / NEUTRALMeanRevComposite
46.60
Technical
92.50
Fundamental
31.40
Rank
—
Price
19.50
Hurst
0.24
As of
Jul 15, 2026
Daily
Erasca, Inc.
HealthcareBiotechnologyErasca is a clinical-stage oncology company developing targeted cancer treatments focused on tumors driven by RAS/MAPK pathway mutations. Its pipeline includes molecular glue and kinase inhibitor candidates designed to treat various solid tumors with RAS and KRAS mutations, as well as an antibody therapy targeting EGFR-driven cancers. The company has established partnerships with multiple organizations to advance its drug candidates through development and commercialization.
Market cap
$5.0B
P/E (trailing)
—
P/E (forward)
-23.03
PEG ratio
—
Dividend yield
0.00%
Beta
0.62
52w range
2.11 – 24.28
Return on equity
-78.25%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 14.35 (+493.0%) · range 2.20–22.47
Cycle position
38/ 100 cycle scoreAPPROACHING ENTRY
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 36 · WEAK SETUP · exit proximity 0
Conviction
26/ 100 · maturity 0%
Buildup.3310
EMA entry setup.4236
Fundamentals.2531
Volume profile
POC
14.87
Price vs POC
-3.5%
Overhead supply
71%
Runway
+0.4%
Value area 12.16–18.30 · 71% of 120d volume overhead · heavy supply
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -12.61% | -8.23% | mature |
| 40d | -24.60% | -8.23% | mature |